

STATISTICAL COMPENDIUM: MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT IN 2005 RHODE ISLAND

LIST OF TABLES

OVERVIEW OF STUDY POPULATION

TABLE 1. OVERVIEW OF BENEFICIARY SELECTION CRITERIA FOR STUDY POPULATION

FOR ALL MEDICAID BENEFICIARIES

TABLE 2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE 3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE 4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE 5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE 6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE 7. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

FOR ALL NONDUAL BENEFICIARIES

TABLE ND.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES. BY BASIS OF ELIGIBILITY

TABLE ND.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE ND.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE ND.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND

BENEFICIARY CHARACTERISTIC

TABLE ND.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE ND.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

TABLE ND.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC

TABLE ND.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND

THERAPEUTIC CATEGORY

TABLE ND.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS,

BY TOP 10 DRUG GROUP

TABLE ND.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS, BY

BENEFICIARY CHARACTERISTIC

TABLE ND.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS PER BENEFIT MONTH,

BY BENEFICIARY CHARACTERISTIC

TABLE ND.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES

AMONG NONDUALS

FOR DUAL ELIGIBLE BENEFICIARIES

TABLE D.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE D.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE D.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE D.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND

BENEFICIARY CHARACTERISTIC

TABLE D.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE D.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

TABLE D.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC

TABLE D.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND

THERAPEUTIC CATEGORY

TABLE D.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS,

BY TOP 10 DRUG GROUP

TABLE D.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS, BY BENEFICIARY CHARACTERISTIC

TABLE D.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS PER BENEFIT MONTH, BY

BENEFICIARY CHARACTERISTIC

TABLE D.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG DUALS

SUPPLEMENTAL TABLES

SUPPLEMENTAL TABLE 1. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES

SUPPLEMENTAL TABLE 1A. MEDICAID PHARMACY REIMBURSEMENT FOR DISABLED DUAL ELIGIBLE BENEFICIARIES UNDER AGE 65

SUPPLEMENTAL TABLE 1B. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 AND OLDER

SUPPLEMENTAL TABLE 1C. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 TO 74 SUPPLEMENTAL TABLE 1D. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 75 TO 84

SUPPLEMENTAL TABLE 1E. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 85 AND OLDER

APPENDIX TABLES

APPENDIX TABLE A.1. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, NONDUAL BENEFICIARIES

APPENDIX TABLE A.2. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, NONDUAL BENEFICIARIES

APPENDIX TABLE A.3. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, DUAL ELIGIBLE BENEFICIARIES

APPENDIX TABLE A.4. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, DUAL

ELIGIBLE BENEFICIARIES

TABLE ND.2 CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY $^{a,\ b}$ NONDUAL BENEFICIARIES, RHODE ISLAND, 2005

		Number of	Beneficia	aries			Nu	mber of Be	enefit Mo	nths	
Δ.II	Anna	Dischlad	مغانيات	Children	Other/	All	۸ مرم ما	Disabled	ماريان	Children	Other/
											Unknown 2,498
39,703	1,023	20,900	14,303	22,900	313	331,301	10,091	221,301	39,100	04,311	2,430
0.004	0	044	0	7.000	0	07.400	0	7.470	0	00.000	0
,				,		,		,			0
						,				,	0
,		,	, -	,		,		,	,	,	58
,		,	,			, -	-	,	,		797
		,				,		,	,		1,640
			5		1	7,049		,	20		3
	328		1		0	3,753	3,330	422	1		0
145	141	4	0	0	0	1,488	1,440	48	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0
33,639	661	10,945	10,500	11,221	312	196,040	6,578	117,281	28,745	40,939	2,497
26,146	362	9,961	4,083	11,739	1	161,947	3,513	104,620	10,441	43,372	1
0	0	0	0	0	0	0	0	0	0	0	0
23,471	188	11,205	5,343	6,500	235	168,561	1,986	120,685	14,583	29,480	1,827
5,578	94	2,367	1,211	1,895	11	38,264	955	24,987	3,659	8,572	91
30,736	741	7,334	8,029	14,565	67	151,162	7,150	76,229	20,944	46,259	580
428	60	368	0	0	0	4,987	661	4,326	0	0	0
322	42	280	0	0	0	3,300	365	2,935	0	0	0
59.035	921	20.258	14.583	22.960	313	349.700	9.065	214.640	39.186	84.311	2,498
,		,	,	,		,	•	,	,	,	,
	180	17.509	2.641	4.122	0	201.380	1.821	188.890	4.133	6.536	0
,			,			,		,	,	,	0
				-							2,498
						,			,		2,490
20,701	001	0,024	. 1,000	11,020	O	102,021	0,207	52,529	55,555	50,450	0
27 501	1 005	10 510	2 0/11	4 721	306	288 085	9 990	21/1521	15 305	<i>15</i> 606	2,483
,	,	,		,		,	,	,	,	,	2,403
									,		6
	33,639 26,146 0 23,471 5,578 30,736	All Aged 59,785 1,023 8,634 0 12,776 0 7,379 0 19,210 0 10,556 1 719 553 366 328 145 141 0 0 33,639 661 26,146 362 0 0 23,471 188 5,578 94 30,736 741 428 60 322 42 59,035 921 3 24,452 180 84 3 8,468 3 26,781 837 27,591 1,005 5,088 12	All Aged Disabled 59,785 1,023 20,906 8,634 0 811 12,776 0 2,362 7,379 0 1,557 19,210 0 7,299 10,556 1 8,676 719 553 160 366 328 37 145 141 4 0 0 0 33,639 661 10,945 26,146 362 9,961 0 0 0 23,471 188 11,205 5,578 94 2,367 30,736 741 7,334 428 60 368 322 42 280 59,035 921 20,258 3 24,452 180 17,509 84 3 73 8,468 3 0 26,781 837 3,324	All Aged Disabled Adults 59,785 1,023 20,906 14,583 8,634 0 811 0 12,776 0 2,362 3 7,379 0 1,557 1,129 19,210 0 7,299 11,751 10,556 1 8,676 1,694 719 553 160 5 366 328 37 1 145 141 4 0 0 0 0 0 26,146 362 9,961 4,083 0 0 0 0 23,471 188 11,205 5,343 5,578 94 2,367 1,211 30,736 741 7,334 8,029 428 60 368 0 322 42 280 0 59,035 921 20,258 14,583 3 24,452 </td <td>59,785 1,023 20,906 14,583 22,960 8,634 0 811 0 7,823 12,776 0 2,362 3 10,411 7,379 0 1,557 1,129 4,680 19,210 0 7,299 11,751 42 10,556 1 8,676 1,694 4 719 553 160 5 0 366 328 37 1 0 0 0 0 0 0 26,146 362 9,961 4,083 11,739 0 0 0 0 0 23,471 188 11,205 5,343 6,500 5,578 94 2,367 1,211 1,895 30,736 741 7,334 8,029 14,565 428 60 368 0 0 59,035 921 20,258 14,583 22,960</td> <td>All Aged Disabled Adults Children Other/Unknown 59,785 1,023 20,906 14,583 22,960 313 8,634 0 811 0 7,823 0 12,776 0 2,362 3 10,411 0 7,379 0 1,557 1,129 4,680 13 19,210 0 7,299 11,751 42 118 10,556 1 8,676 1,694 4 181 719 553 160 5 0 1 366 328 37 1 0 0 45 141 4 0 0 0 33,639 661 10,945 10,500 11,221 312 26,146 362 9,961 4,083 11,739 1 0 0 0 0 0 0 23,471 188 11,205 5,343 6,500<td>All Aged Disabled Adults Children Unknown All 59,785 1,023 20,906 14,583 22,960 313 357,987 8,634 0 811 0 7,823 0 27,402 12,776 0 2,362 3 10,411 0 68,334 7,379 0 1,557 1,129 4,680 13 38,339 19,210 0 7,299 11,751 42 118 111,077 10,556 1 8,676 1,694 4 181 100,545 719 553 160 5 0 1 7,049 366 328 37 1 0 0 3,753 145 141 4 0 0 0 0 26,146 362 9,961 4,083 11,739 1 161,947 0 0 0 0 0 0 0 0<td>All Aged Disabled Adults Children Unknown All Aged 59,785 1,023 20,906 14,583 22,960 313 357,987 10,091 8,634 0 811 0 7,823 0 27,402 0 12,776 0 2,362 3 10,411 0 68,334 0 7,379 0 1,557 1,129 4,680 13 38,339 0 19,210 0 7,299 11,751 42 118 111,077 0 10,556 1 8,676 1,694 4 181 100,545 7 719 553 160 5 0 1 7,049 5,314 366 328 37 1 0 0 3,753 3,330 145 141 4 0 0 0 0 0 0 26,146 362 9,961 4,083</td><td>All Aged Disabled Adults Children Unknown All Aged Disabled 59,785 1,023 20,906 14,583 22,960 313 357,987 10,091 221,901 8,634 0 811 0 7,823 0 27,402 0 7,172 12,776 0 2,362 3 10,411 0 68,334 0 25,210 7,379 0 1,557 1,129 4,680 13 38,339 0 15,947 19,210 0 7,299 11,751 42 118 111,077 0 78,441 10,556 1 8,676 1,694 4 181 10,0545 7 92,949 719 553 160 5 0 1 7,049 5,314 1,712 366 328 37 1 0 0 3,753 3,330 422 145 141 4 0</td><td>All Aged Disabled Adults Children Other/ Unknown All Aged Disabled Adults 59,785 1,023 20,906 14,583 22,960 313 357,987 10,091 221,901 39,186 8,634 0 811 0 7,823 0 27,402 0 7,172 0 12,776 0 2,362 3 10,411 0 68,334 0 25,210 6 7,379 0 1,557 1,129 4,680 13 38,339 0 15,947 1,706 19,210 0 7,299 11,751 42 118 111,077 0 78,441 31,540 10,556 1 8,676 1,694 4 181 10,0749 5,314 1,712 20 366 328 37 1 0 0 3,753 3,330 422 1 145 141 4 0 0 <t< td=""><td>All Aged Disabled Adults Children Other/Unknown All Aged Disabled Adults Children 59,785 1,023 20,906 14,583 22,960 313 357,987 10,091 221,901 39,186 84,311 8,634 0 23,322 3 10,411 0 68,334 0 25,210 6 43,118 7,379 0 1,557 1,129 4,680 13 38,339 0 15,947 1,706 20,628 19,210 0 7,299 11,751 42 118 111,077 0 78,441 31,540 299 10,556 1 8,676 1,694 4 181 10,0745 5,14 1,712 20 0 366 328 37 1 0 0 3,753 3,330 422 1 0 4 141 4 0 0 0 0 1,488 1,440</td></t<></td></td></td>	59,785 1,023 20,906 14,583 22,960 8,634 0 811 0 7,823 12,776 0 2,362 3 10,411 7,379 0 1,557 1,129 4,680 19,210 0 7,299 11,751 42 10,556 1 8,676 1,694 4 719 553 160 5 0 366 328 37 1 0 0 0 0 0 0 26,146 362 9,961 4,083 11,739 0 0 0 0 0 23,471 188 11,205 5,343 6,500 5,578 94 2,367 1,211 1,895 30,736 741 7,334 8,029 14,565 428 60 368 0 0 59,035 921 20,258 14,583 22,960	All Aged Disabled Adults Children Other/Unknown 59,785 1,023 20,906 14,583 22,960 313 8,634 0 811 0 7,823 0 12,776 0 2,362 3 10,411 0 7,379 0 1,557 1,129 4,680 13 19,210 0 7,299 11,751 42 118 10,556 1 8,676 1,694 4 181 719 553 160 5 0 1 366 328 37 1 0 0 45 141 4 0 0 0 33,639 661 10,945 10,500 11,221 312 26,146 362 9,961 4,083 11,739 1 0 0 0 0 0 0 23,471 188 11,205 5,343 6,500 <td>All Aged Disabled Adults Children Unknown All 59,785 1,023 20,906 14,583 22,960 313 357,987 8,634 0 811 0 7,823 0 27,402 12,776 0 2,362 3 10,411 0 68,334 7,379 0 1,557 1,129 4,680 13 38,339 19,210 0 7,299 11,751 42 118 111,077 10,556 1 8,676 1,694 4 181 100,545 719 553 160 5 0 1 7,049 366 328 37 1 0 0 3,753 145 141 4 0 0 0 0 26,146 362 9,961 4,083 11,739 1 161,947 0 0 0 0 0 0 0 0<td>All Aged Disabled Adults Children Unknown All Aged 59,785 1,023 20,906 14,583 22,960 313 357,987 10,091 8,634 0 811 0 7,823 0 27,402 0 12,776 0 2,362 3 10,411 0 68,334 0 7,379 0 1,557 1,129 4,680 13 38,339 0 19,210 0 7,299 11,751 42 118 111,077 0 10,556 1 8,676 1,694 4 181 100,545 7 719 553 160 5 0 1 7,049 5,314 366 328 37 1 0 0 3,753 3,330 145 141 4 0 0 0 0 0 0 26,146 362 9,961 4,083</td><td>All Aged Disabled Adults Children Unknown All Aged Disabled 59,785 1,023 20,906 14,583 22,960 313 357,987 10,091 221,901 8,634 0 811 0 7,823 0 27,402 0 7,172 12,776 0 2,362 3 10,411 0 68,334 0 25,210 7,379 0 1,557 1,129 4,680 13 38,339 0 15,947 19,210 0 7,299 11,751 42 118 111,077 0 78,441 10,556 1 8,676 1,694 4 181 10,0545 7 92,949 719 553 160 5 0 1 7,049 5,314 1,712 366 328 37 1 0 0 3,753 3,330 422 145 141 4 0</td><td>All Aged Disabled Adults Children Other/ Unknown All Aged Disabled Adults 59,785 1,023 20,906 14,583 22,960 313 357,987 10,091 221,901 39,186 8,634 0 811 0 7,823 0 27,402 0 7,172 0 12,776 0 2,362 3 10,411 0 68,334 0 25,210 6 7,379 0 1,557 1,129 4,680 13 38,339 0 15,947 1,706 19,210 0 7,299 11,751 42 118 111,077 0 78,441 31,540 10,556 1 8,676 1,694 4 181 10,0749 5,314 1,712 20 366 328 37 1 0 0 3,753 3,330 422 1 145 141 4 0 0 <t< td=""><td>All Aged Disabled Adults Children Other/Unknown All Aged Disabled Adults Children 59,785 1,023 20,906 14,583 22,960 313 357,987 10,091 221,901 39,186 84,311 8,634 0 23,322 3 10,411 0 68,334 0 25,210 6 43,118 7,379 0 1,557 1,129 4,680 13 38,339 0 15,947 1,706 20,628 19,210 0 7,299 11,751 42 118 111,077 0 78,441 31,540 299 10,556 1 8,676 1,694 4 181 10,0745 5,14 1,712 20 0 366 328 37 1 0 0 3,753 3,330 422 1 0 4 141 4 0 0 0 0 1,488 1,440</td></t<></td></td>	All Aged Disabled Adults Children Unknown All 59,785 1,023 20,906 14,583 22,960 313 357,987 8,634 0 811 0 7,823 0 27,402 12,776 0 2,362 3 10,411 0 68,334 7,379 0 1,557 1,129 4,680 13 38,339 19,210 0 7,299 11,751 42 118 111,077 10,556 1 8,676 1,694 4 181 100,545 719 553 160 5 0 1 7,049 366 328 37 1 0 0 3,753 145 141 4 0 0 0 0 26,146 362 9,961 4,083 11,739 1 161,947 0 0 0 0 0 0 0 0 <td>All Aged Disabled Adults Children Unknown All Aged 59,785 1,023 20,906 14,583 22,960 313 357,987 10,091 8,634 0 811 0 7,823 0 27,402 0 12,776 0 2,362 3 10,411 0 68,334 0 7,379 0 1,557 1,129 4,680 13 38,339 0 19,210 0 7,299 11,751 42 118 111,077 0 10,556 1 8,676 1,694 4 181 100,545 7 719 553 160 5 0 1 7,049 5,314 366 328 37 1 0 0 3,753 3,330 145 141 4 0 0 0 0 0 0 26,146 362 9,961 4,083</td> <td>All Aged Disabled Adults Children Unknown All Aged Disabled 59,785 1,023 20,906 14,583 22,960 313 357,987 10,091 221,901 8,634 0 811 0 7,823 0 27,402 0 7,172 12,776 0 2,362 3 10,411 0 68,334 0 25,210 7,379 0 1,557 1,129 4,680 13 38,339 0 15,947 19,210 0 7,299 11,751 42 118 111,077 0 78,441 10,556 1 8,676 1,694 4 181 10,0545 7 92,949 719 553 160 5 0 1 7,049 5,314 1,712 366 328 37 1 0 0 3,753 3,330 422 145 141 4 0</td> <td>All Aged Disabled Adults Children Other/ Unknown All Aged Disabled Adults 59,785 1,023 20,906 14,583 22,960 313 357,987 10,091 221,901 39,186 8,634 0 811 0 7,823 0 27,402 0 7,172 0 12,776 0 2,362 3 10,411 0 68,334 0 25,210 6 7,379 0 1,557 1,129 4,680 13 38,339 0 15,947 1,706 19,210 0 7,299 11,751 42 118 111,077 0 78,441 31,540 10,556 1 8,676 1,694 4 181 10,0749 5,314 1,712 20 366 328 37 1 0 0 3,753 3,330 422 1 145 141 4 0 0 <t< td=""><td>All Aged Disabled Adults Children Other/Unknown All Aged Disabled Adults Children 59,785 1,023 20,906 14,583 22,960 313 357,987 10,091 221,901 39,186 84,311 8,634 0 23,322 3 10,411 0 68,334 0 25,210 6 43,118 7,379 0 1,557 1,129 4,680 13 38,339 0 15,947 1,706 20,628 19,210 0 7,299 11,751 42 118 111,077 0 78,441 31,540 299 10,556 1 8,676 1,694 4 181 10,0745 5,14 1,712 20 0 366 328 37 1 0 0 3,753 3,330 422 1 0 4 141 4 0 0 0 0 1,488 1,440</td></t<></td>	All Aged Disabled Adults Children Unknown All Aged 59,785 1,023 20,906 14,583 22,960 313 357,987 10,091 8,634 0 811 0 7,823 0 27,402 0 12,776 0 2,362 3 10,411 0 68,334 0 7,379 0 1,557 1,129 4,680 13 38,339 0 19,210 0 7,299 11,751 42 118 111,077 0 10,556 1 8,676 1,694 4 181 100,545 7 719 553 160 5 0 1 7,049 5,314 366 328 37 1 0 0 3,753 3,330 145 141 4 0 0 0 0 0 0 26,146 362 9,961 4,083	All Aged Disabled Adults Children Unknown All Aged Disabled 59,785 1,023 20,906 14,583 22,960 313 357,987 10,091 221,901 8,634 0 811 0 7,823 0 27,402 0 7,172 12,776 0 2,362 3 10,411 0 68,334 0 25,210 7,379 0 1,557 1,129 4,680 13 38,339 0 15,947 19,210 0 7,299 11,751 42 118 111,077 0 78,441 10,556 1 8,676 1,694 4 181 10,0545 7 92,949 719 553 160 5 0 1 7,049 5,314 1,712 366 328 37 1 0 0 3,753 3,330 422 145 141 4 0	All Aged Disabled Adults Children Other/ Unknown All Aged Disabled Adults 59,785 1,023 20,906 14,583 22,960 313 357,987 10,091 221,901 39,186 8,634 0 811 0 7,823 0 27,402 0 7,172 0 12,776 0 2,362 3 10,411 0 68,334 0 25,210 6 7,379 0 1,557 1,129 4,680 13 38,339 0 15,947 1,706 19,210 0 7,299 11,751 42 118 111,077 0 78,441 31,540 10,556 1 8,676 1,694 4 181 10,0749 5,314 1,712 20 366 328 37 1 0 0 3,753 3,330 422 1 145 141 4 0 0 <t< td=""><td>All Aged Disabled Adults Children Other/Unknown All Aged Disabled Adults Children 59,785 1,023 20,906 14,583 22,960 313 357,987 10,091 221,901 39,186 84,311 8,634 0 23,322 3 10,411 0 68,334 0 25,210 6 43,118 7,379 0 1,557 1,129 4,680 13 38,339 0 15,947 1,706 20,628 19,210 0 7,299 11,751 42 118 111,077 0 78,441 31,540 299 10,556 1 8,676 1,694 4 181 10,0745 5,14 1,712 20 0 366 328 37 1 0 0 3,753 3,330 422 1 0 4 141 4 0 0 0 0 1,488 1,440</td></t<>	All Aged Disabled Adults Children Other/Unknown All Aged Disabled Adults Children 59,785 1,023 20,906 14,583 22,960 313 357,987 10,091 221,901 39,186 84,311 8,634 0 23,322 3 10,411 0 68,334 0 25,210 6 43,118 7,379 0 1,557 1,129 4,680 13 38,339 0 15,947 1,706 20,628 19,210 0 7,299 11,751 42 118 111,077 0 78,441 31,540 299 10,556 1 8,676 1,694 4 181 10,0745 5,14 1,712 20 0 366 328 37 1 0 0 3,753 3,330 422 1 0 4 141 4 0 0 0 0 1,488 1,440

a. Table ND.2 includes the beneficiaries represented by Cell K of Table 1. Benefit months error months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; Rx = pharmacy benefit.

TABLE ND.3

ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC^{a, b}

NONDUAL BENEFICIARIES, RHODE ISLAND, 2005

Beneficiary	Percentage with	Mean Number	Mara Du C	Ć D.	Mean \$, All Medicaid	Rx \$ as a Percentage of All Medicaid	Number of
Characteristics All	at Least One Rx	of Rx 11.8	Mean Rx \$	\$ per Rx \$81		FFS \$ ^d	Beneficiaries 59,785
	41.0	11.0	φ900	фот	\$8,031	11.9	59,765
Age	47.0	4.0	00	5 4	0.540	4.0	0.004
5 and younger	17.8	1.2	66	54	,	1.9	8,634
6-14	30.3	3.6	192	54	,	4.6	12,776
15-20	29.6	4.2	258	61	8,647	3.0	7,379
21-44	43.5 76.4	11.3	984	87	•	11.8	19,210
45-64		34.9	2,953	85		19.6	10,556
65-74	79.1	21.7	1,528	70	,	20.2	719
75-84	79.8	25.6	1,756	69	•	15.9	366
85 and older	82.8	39.1	2,317	59		9.8	145
Unknown	0.0	0.0	0	0	0	0.0	0
Basis of Eligibilitye							
Aged	78.4	22.4	1,495	67	,	14.7	1,023
Disabled	78.9	29.6	2,561	86	,	14.4	20,906
Adults	21.5	1.9	48	25	,	2.2	14,583
Children	18.8	1.3	43	34	•	1.6	22,960
Unknown	75.1	14.0	1,036	74	8,203	12.6	313
Gender							
Female	43.3	13.5	1,044	77	•	14.4	33,639
Male	39.9	9.6	841	88		9.3	26,146
Unknown	0.0	0.0	0	0	0	0.0	0
Race							
White	53.4	18.9	1,530	81	11,968	12.8	23,471
African American	45.1	10.6	940	89	8,227	11.4	5,578
Other/unknown	32.3	6.6	518	79	4,990	10.4	30,736
Use of Nursing Facil	lities ^f						
Entire year	86.7	64.9	5,103	79	136,370	3.7	428
Part year	92.5	75.3	5,801	77	97,866	5.9	322
None	41.2	11.1	898	81	6,611	13.6	59,035
Maintenance Assista	ance Status						
Cash	60.2	22.6	1,990	88	13,329	14.9	24,452
Medically needy	91.7	35.8	3,225	90	39,516	8.2	84
Poverty related	15.2	1.0	51	50	1,786	2.8	8,468
Other/unknown	33.3	5.3	288	55	5,070	5.7	26,781

a. Table ND.3 includes beneficiaries represented by Cell K of Table 1.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.

d. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.

e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability

e, interuction dates or engoting to classificate dates, accept, academy and classificate group includes beneficially say who were determined to be engine because or disability or blindness. The children's group includes children's group children's group children's group children's group children's group

f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.4 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC^{a, b} NONDUAL BENEFICIARIES, RHODE ISLAND, 2005

			_		Nur	nber of Rx, F	Percentage w	vith:		_	Numbe	r
Beneficiary Characteristics	Mean Number of Rx	Mean Rx \$	Rx \$ as a Percentage of All Medicaid FFS \$c	None		More than 1, but 2 or Less	More than 2, but 5 or Less	More than 5, but 10 or Less		Mean \$, All Medicaid FFS \$d	Beneficiaries	Benefit Months
All	2.0	\$159	11.9	58.2	19.3	6.5	10.1	4.8	1.1	\$1,341	59,785	357,987
Age												
5 and younger	0.4	21	1.9	82.2	14.2	2.0	1.3	0.2	0.0	1,109	8,634	27,402
6-14	0.7	36	4.6	69.7	21.7	4.4	3.7	0.5	0.0	782	12,776	68,334
15-20	0.8	50	3.0	70.4	19.8	4.3	4.5	1.0	0.1	1,664	7,379	38,339
21-44	2.0	170	11.8	56.5	19.8	7.2	11.0	4.5	0.9	1,445	19,210	111,077
45-64	3.7	310	19.6	23.6	18.2	11.7	26.0	16.2	4.3	1,582	10,556	100,545
65-74	2.2	156	20.2	20.9	32.4	18.1	20.0	7.1	1.5	771	719	7,049
75-84	2.5	171	15.9	20.2	31.1	16.1	21.0	9.8	1.6	1,081	366	3,753
85 and older	3.8	226	9.8	17.2	13.1	12.4	31.0	22.1	4.1	2,308	145	1,488
Unknown	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0	0
Basis of Eligibility	_/ e											
Aged	2.3	152	14.7	21.6	31.8	17.4	19.8	7.9	1.5	1,029	1,023	10,091
Disabled	2.8	241	14.4	21.1	27.4	12.3	23.6	12.6	3.0	1,681	20,906	221,901
Adults	0.7	18	2.2	78.5	13.0	4.0	3.6	0.7	0.2	807	14,583	39,186
Children	0.3	12	1.6	81.2	15.2	2.1	1.3	0.1	0.0	741	22,960	84,311
Unknown	1.7	130	12.6	24.9	37.7	15.0	17.9	4.2	0.3	1,028	313	2,498
Gender												
Female	2.3	179	14.4	56.7	18.5	6.6	10.9	5.8	1.5	1,245	33,639	196,040
Male	1.5	136	9.3	60.1	20.4	6.3	9.0	3.5	0.7	1,457	26,146	161,947
Unknown	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0	0
Race												
White	2.6	213	12.8	46.6	19.9	8.3	14.6	8.5	2.2	1,666	23,471	168,561
African American	1.5	137	11.4	54.9	24.3	6.8	9.4	3.9	0.7	1,199	5,578	38,264
Other/unknown	1.3	105	10.4	67.7	18.0	5.1	6.8	2.1	0.4	1,015	30,736	151,162
Use of Nursing Fa	cilities ^f											
Entire year	5.6	438	3.7	13.3	5.8	7.5	29.4	31.1	12.9	11,704	428	4,987
Part year	7.3	566	5.9	7.5	7.5	8.7	21.4	29.8	25.2	9,549	322	3,300
None	1.9	152	13.6	58.8	19.5	6.5	9.9	4.4	0.9	1,116	59,035	349,700
Maintenance Assi	stance Status	3										
Cash	2.7	242	14.9	39.8	21.1	9.2	17.7	9.8	2.3	1,618	24,452	201,380
Medically needy	4.1	373	8.2	8.3	14.3	19.0	32.1	22.6	3.6	4,572	84	726
Poverty related	0.4	19	2.8	84.8	11.8	1.9	1.3	0.2	0.0	650	8,468	23,254
Other/unknown	1.1	58	5.7	66.7	20.1	5.4	5.8	1.6	0.4	1,024	26,781	132,627

a. Table ND.4 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
c. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.

d. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability

or blindness. The children's group includes children receiving foster care and adoptive services.

f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.5

AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC^{A, b, c}

NONDUAL BENEFICIARIES, RHODE ISLAND, 2005

		All Rx		Patente	d Brand Drugs	d-Name	Off-Pater	nt Bran Drugs	id-Name	Gen	eric Dı	une
Danafisian	Nivershous	All IX		Niconala a u	Diugs			Diugs		Number	enc Di	uys
Beneficiary Characteristics	Number of Rx	Rx\$	\$ per Rx	Number of Rx	Rx\$	\$ per Rx	Number of Rx	Rx\$	\$ per Rx	of Rx	Rx\$	\$ per Rx
All	2.0		\$81	0.8	\$119	\$147	0.1	\$9	\$128	1.1	\$31	\$29
Age												
5 and younger	0.4	21	54	0.2	18	114	0.0	1	42	0.2	2	11
6-14	0.7	36	54	0.4	29	80	0.0	2	63	0.3	5	19
15-20	0.8	50	61	0.4	37	95	0.0	2	63	0.4	10	27
21-44	2.0	170	87	0.8	131	170	0.1	8	113	1.1	31	28
45-64	3.7	310	85	1.5	225	154	0.1	21	157	2.1	64	3
65-74	2.2	156	70	1.0	118	118	0.1	6	96	1.2	32	28
75-84	2.5	171	69	1.2	133	113	0.1	4	83	1.3	34	27
85 and older	3.8	226	59	1.6	167	108	0.1	7	65	2.1	52	24
Unknown	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	(
Basis of Eligibility	rd											
Aged	2.3	152	67	1.0	116	113	0.0	4	78	1.2	31	26
Disabled	2.8	241	86	1.1	180	158	0.1	14	136	1.5	47	30
Adults	0.7	18	25	0.3	12	42	0.0	1	30	0.4	5	13
Children	0.3	12	34	0.2	9	51	0.0	1	53	0.2	2	14
Unknown	1.7	130	74	0.6	99	153	0.0	3	75	1.1	28	26
Gender												
Female	2.3	179	77	0.9	133	143	0.1	10	113	1.3	36	28
Male	1.5	136	88	0.7	103	153	0.1	8	158	0.8	25	30
Unknown	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	(
Race												
White	2.6	213	81	1.1	156	146	0.1	14	134	1.5	43	30
African American	1.5	137	89	0.6	105	171	0.1	8	157	0.9	24	27
Other/unknown	1.3	105	79	0.6	81	142	0.0	4	102	0.7	20	27
Use of Nursing Fa	cilitiese											
Entire year	5.6	438	79	2.2	314	144	0.2	28	117	3.1	95	30
Part year	7.3	566	77	2.8	434	157	0.2	19	109	4.4	113	26
None	1.9	152	81	0.8	113	147	0.1	9	129	1.0	30	29
Maintenance Assi	stance Sta	tus										
Cash	2.7	242	88	1.1	181	163	0.1	14	142	1.5	47	3
Medically needy	4.1	373	90	1.6	286	183	0.1	12	161	2.5	75	30
Poverty related	0.4	19	50	0.1	14	100	0.0	0	56	0.2	4	18
Other/unknown	1.1	58	55	0.5	44	91	0.0	3	74	0.5	12	22

a. Table ND.5 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Rhode Island, 0.4 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

d. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability

or blindness. The children's group includes children receiving foster care and adoptive services.

e. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.6

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY^{a, b, c, d}

NONDUAL BENEFICIARIES, RHODE ISLAND, 2005

			x per Ben long User		\$ per	Benefit N Us	Month Amers	ong		\$ per	Rx					Userse	
Therapeutic Category	F Total	Patented Brand- Name		Generic		atented Brand- Name	Off- Patent Brand- Name G	eneric	F Total	atented Brand- Name	Brand-	Generic	Total Number of Rx	Total Rx \$	Number of	of All	Benefit
Anti-infective Agents	0.3	0.1	0.0	0.2	\$38	\$29	\$4	\$5	\$122	\$304	\$102	\$27	45,572	\$5,540,316	13,600	22.7	145,464
Biologicals	0.4	0.3	0.0	0.1	752	578	0	175	2023	1,994	0	2,123	122	246,773	40	0.1	328
Antineoplastic Agents	0.5	0.2	0.0	0.3	147	124	0	23	279	645	214	69	2,249	628,254	396	0.7	4,269
Endocrine/Metabolic Drugs	0.6	0.2	0.0	0.3	40	27	4	9	68	125	92	27	48,618	3,295,518	7,845	13.1	83,265
Cardiovascular Agents	0.9	0.5	0.0	0.5	62	49	0	12	67	107	84	26	89,635	6,000,465	8,962	15.0	97,491
Respiratory Agents	0.7	0.4	0.0	0.2	38	33	2	3	58	83	65	12	68,581	3,974,983	9,688	16.2	104,619
Gastrointestinal Agents	0.6	0.3	0.0	0.3	61	48	1	12	102	162	106	41	48,322	4,937,482	7,254	12.1	80,444
Genitourinary Agents	0.3	0.2	0.0	0.1	20	16	1	3	58	79	58	24	7,899	460,970	2,067	3.5	22,684
CNS Drugs	1.3	0.6	0.0	0.7	127	104	2	21	99	177	126	31	169,827	16,839,591	12,327	20.6	132,240
Stimulants/Anti-obesity/Anorexia	0.8	0.6	0.0	0.2	46	40	1	5	62	70	77	29	16,269	1,001,302	2,082	3.5	21,612
Miscellaneous Psychological/ Neurological Agents	0.5	0.5	0.0	0.0	168	168	0	0	350	360	0	21	1,381	483,569			2,870
Analgesics and Anesthetics	0.7	0.1	0.0	0.6	38	13	10	15	55	156	254	26	91,662	5,077,448	,		,
Neuromuscular Agents	0.8	0.3	0.0	0.5	61	40	4	18	77	149	103	36	63,229	4,857,450	,		79,044
Nutritional Products	0.4	0.0	0.0	0.3	7	1	0	6	20	30	65	19	4,762	96,275	,	2.3	- ,
Hematological Agents	0.6	0.2	0.0	0.4	88	81	1	6	143	360	53	16	10,901	1,559,384	1,622	2.7	17,776
Topical Products	0.3	0.1	0.0	0.2	15	9	0	5	46	84	52	24	32,191	1,474,073	9,284	15.5	101,560
Miscellaneous Products	0.3	0.2	0.0	0.1	61	42	3	15	208	263	189	133	2,820	585,404	896	1.5	9,589
Unknown Therapeutic Category	0.2	0.0	0.0	0.0	9	0	0	0	52	0	0	0	419	21,769	203	0.3	2,328
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	704,459	57,081,026	n.a.	n.a.	n.a.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.6 includes the beneficiaries represented by Cell K of Table 1. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum

of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

d. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Rhode Island, 0.4 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

e. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2005.

TABLE ND.7 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP^{a, b, c} NONDUAL BENEFICIARIES, RHODE ISLAND, 2005

	<u>-</u>		Users		Am	nong User	rs
Top 10 Drug Groups	Total Medicaid Rx \$	Number of Users	As a Percentage of All Beneficiaries	Number of Benefit Months	Number of Rx per Benefit Month	\$ per Rx	Rx \$ per Benefit Month
ANTIPSYCHOTICS	\$10,408,961	6,355	10.6	71,512	0.7	\$216	\$146
ANTIDEPRESSANTS	5,026,088	13,417	22.4	148,981	0.6	61	34
ANTICONVULSANT	4,398,029	6,193	10.4	69,764	0.7	92	63
ANTIVIRAL	3,985,942	1,535	2.6	17,244	0.5	493	231
ULCER DRUGS	3,715,184	6,939	11.6	78,576	0.5	101	47
ANALGESICS - Narcotic	3,126,653	12,869	21.5	143,882	0.4	55	22
ANTIASTHMATIC	2,831,229	10,329	17.3	115,287	0.4	65	25
ANTIHYPERLIPIDEMIC	2,542,854	4,738	7.9	53,544	0.6	85	47
ANTIDIABETIC	2,115,581	4,567	7.6	51,376	0.5	86	41
ANTIHYPERTENSIVE	1,311,156	5,506	9.2	61,442	0.4	58	21
Total	39,461,677	72,448		811,608	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2005 file for Rhode Island, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Table ND.7 includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$

⁼ Medicaid reimbursement.

TABLE ND.7A MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS COMBINED AND FIRST AND SECOND GROUPS SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c} NONDUAL BENEFICIARIES, RHODE ISLAND, 2005

	All Top 10	Drug Groups		ANTI	PSYCHOTIC	S			AN	TIDEPRESS/	ANTS	
Beneficiary Characteristics	Number of Rx	Rx \$	Number of Users	Users as % of All Benes	Number of Benefit N Months Among Users		Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit I Months Among Users	Mean Number of Rx per Benefit Month	Mean Rx \$ per Benefit Month
All	400,703	\$39,461,677	6,355	10.6	71,512	0.7	\$146	13,417	22.4	148,981	0.6	\$34
Female												
All Females	255,708	23,802,548	3,505	10.4	39,711	0.6	135	9,209	27.4	102,481	0.5	34
Female, Disabled												
All Ages	235,589	22,783,004	3,287	30.0	37,672	0.7	139	8,211	75.0	93,375	0.6	36
5 and younger	803	55,036	1	0.3	12	0.1	3	4	1.3	48	0.3	16
6-14	3,782	284,870	71	9.8	807	0.6	66	87	12.0	929	0.6	21
15-20	4,083	314,580	83	14.6	937	0.7	87	156	27.5	1,753	0.5	26
21-44	73,915	7,790,220	1,551	40.0	17,643	0.6	131	3,154	81.4	35,714	0.5	35
45-64	150,102	14,112,818	1,566	29.3	18,118	0.7	153	4,745	88.7	54,208	0.6	37
65-74	2,323	187,071	11	10.2	110	0.9	246	49	45.4	531	0.5	26
75-84	522	35,707	3	16.7	33	0.4	21	14	77.8	168	0.7	41
85 and older	59	2,702	1	25.0	12	1.2	132	2	50.0	24	0.6	8
Female, Other Eligibles												
All Ages	20,119	1,019,544	218	1.0	2,039	0.5	66	998	4.4	9,106	0.5	16
5 and younger	337	6,918	0	0.0	0	0.0	0	0	0.0	0	0.0	0
6-14	2,036	73,277	39	8.0	406	0.6	68	66	1.3	686	0.5	9
15-20	1,289	72,627	42	1.3	441	0.7	85	64	2.0	650	0.4	15
21-44	6,665	180,360	59	0.7	452	0.3	30	546	6.3	4,641	0.4	12
45-64	3,192	158,835	29	2.5	232	0.3	28	176	15.2	1,544	0.5	22
65-74	2,997	255,660	8	2.1	84	0.4	69	61	16.2	684	0.4	16
75-84	1,962	162,855	17	8.8	179	0.5	115	42	21.6	475	0.5	25
85 and older	1,641	109,012	24	26.1	245	0.6	93	43	46.7	426	0.7	38
Male												
All Males	144,995	15,659,129	2,850	10.9	31,801	0.7	158	4,208	16.1	46,500	0.6	33
Male, Disabled												
All Ages	132,351	15,035,256	2,648	26.6	29,703	0.7	165	3,886	39.0	43,428	0.6	34
5 and younger	1,404	82,733	3	0.6	30	0.9	43	9	1.8	82	0.3	7
6-14	9,890	680,119	317	19.3	3,518	0.6	74	256	15.6	2,894	0.6	20
15-20	6,672	507,913	205	20.7	2,274	0.7	94	202	20.4	2,288	0.6	27
21-44	45,776	6,103,968	1,270	37.1	14,330	0.7	192	1,590	46.4	17,757	0.6	37
45-64	67,207	7,512,305	837	25.2	9,368	0.7	175	1,802	54.2	20,101	0.6	34
65-74	900	94,303	13	25.0	147	0.8	183	17	32.7	186	0.5	33
75-84	502	53,915	3	15.8	36	0.6	369	10	52.6	120	0.3	16
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

TABLE ND.7A MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS COMBINED AND FIRST AND SECOND GROUPS SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND $\mathsf{AGE}^{\mathsf{a},\;\mathsf{b},\;\mathsf{c}}$ NONDUAL BENEFICIARIES, RHODE ISLAND, 2005

	All Top 10 D	rug Groups		ANTI	PSYCHOTIC	S			AN ⁻	TIDEPRESSA	NTS	
Beneficiary Characteristics	Number of Rx	Rx \$	Number of Users	Users as % of All Benes	Number of Benefit N Months Among Users	Mean Iumber of Rx per I Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Months Among	Mean lumber of Rx per Benefit Month	Mean Rx \$ per Benefit Month
Male, Other Eligibles												
All Ages	12,644	623,873	202	1.2	2,098	0.6	69	322	2.0	3,072	0.5	21
5 and younger	730	14,926	2	0.0	24	0.5	11	7	0.2	53	0.2	4
6-14	3,386	137,794	87	1.6	923	0.6	63	81	1.5	832	0.6	15
15-20	1,876	111,005	68	2.7	729	0.7	76	69	2.7	703	0.7	28
21-44	1,585	41,819	11	0.3	77	0.7	32	71	2.2	530	0.5	18
45-64	1,449	37,382	6	0.8	51	0.3	45	26	3.6	194	0.5	15
65-74	1,647	132,867	12	6.6	134	0.6	96	27	14.8	305	0.5	24
75-84	1,309	103,087	9	6.7	79	0.5	82	23	17.0	251	0.5	28
85 and older	662	44,993	7	14.3	81	0.6	78	18	36.7	204	0.5	20
Unknown	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2005 file for Rhode Island, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Table ND.7A includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan. com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription (s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7B MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY,

BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c} NONDUAL BENEFICIARIES, RHODE ISLAND, 2005

ULCER DRUGS ANTICONVULSANT **ANTIVIRAL** Number of Mean Number of Mean Number of Mean Users Benefit Number of Mean Users Benefit Number of Mean Users Benefit Number of Mean Rx per Rx \$ per as % as % Months Months Rx per Rx \$ per as % Months Rx per Rx \$ per Benefit Benefit Number of of All Among Benefit Benefit Number of of All Among Benefit Benefit Number of of All Among **Beneficiary Characteristics** Benes Benes Users Month Users Users Month Month Users Benes Users Month Month Users Month ΑII 6.193 10.4 69.764 0.7 \$63 1.535 2.6 17.244 0.5 \$231 6.939 11.6 78.576 0.5 \$47 Female All Females 3,911 11.6 43,932 0.7 61 966 2.9 10,861 0.4 186 4,645 13.8 52,742 0.5 48 Female, Disabled All Ages 3,632 33.2 41,417 0.7 63 855 7.8 9,761 0.4 204 4,078 37.3 47,021 0.5 50 61 5 and younger 36 12.0 412 0.5 1 0.3 12 0.1 3 41 13.6 435 0.5 36 6-14 43 131 18.1 1,546 0.7 70 18 2.5 204 0.6 126 68 9.4 792 0.5 15-20 132 23.3 1.519 0.8 82 10 1.8 120 0.2 9 88 15.5 1.030 0.3 32 21-44 1,499 38.7 16,959 0.7 69 411 10.6 4,668 0.4 209 1,208 31.2 13,861 0.4 42 45-64 1,812 33.9 20,740 0.7 58 413 7.7 4,733 0.4 209 2,608 48.7 30,187 0.5 55 65-74 17 15.7 184 0.6 24 2 1.9 24 0.1 8 55 50.9 599 0.5 50 57 65 0 75-84 5 27.8 1.5 0 0.0 0 0.0 9 50.0 105 0.5 59 0.0 0 0 0 25.0 33 85 and older 0 0.0 0 0.0 0.0 0 12 0.4 Female, Other Eligibles All Ages 279 1.2 2,515 0.5 19 111 0.5 1,100 0.2 31 567 2.5 5,721 0.4 26 9 0.2 80 0.5 13 0.0 0 0.0 0 12 93 14 0 0.3 0.5 5 and younger 6-14 36 0.7 383 0.7 20 11 0.2 122 0.1 2 32 0.6 343 0.4 36 15-20 18 0.5 175 0.5 24 10 0.3 119 0.2 11 38 1.2 384 0.2 20 21-44 139 1.6 1,099 0.4 14 73 0.8 672 0.3 20 205 2.4 1,913 0.3 10 45-64 36 3.1 320 0.5 21 13 1.1 145 0.3 107 85 7.3 846 0.4 26 65-74 12 3.2 137 0.3 19 2 0.5 24 0.3 139 95 25.2 1.058 0.4 38 75-84 15 7.7 160 0.5 34 0.5 12 0.3 36 59 30.4 643 42 0.4 85 and older 14 15.2 161 0.6 22 6 0.2 16 41 44.6 441 0.6 43 1.1 Male All Males 2,282 8.7 25,832 0.7 67 569 2.2 6,383 0.6 307 2,294 25,834 0.5 47 8.8 Male, Disabled All Ages 21.6 6,005 326 2,026 23,132 49 2,156 24,569 0.7 69 535 5.4 0.6 20.3 0.5 39 7.6 438 0.4 44 2 24 2 96 1,054 35 5 and younger 0.4 0.1 18.8 0.5 6-14 250 15.2 2,827 0.7 50 24 1.5 276 0.2 56 123 7.5 1,436 0.5 47 15-20 163 16.5 1,858 0.8 79 10 1.0 120 0.1 5 73 7.4 841 0.4 37 21-44 899 26.2 10.357 84 198 2.217 0.6 306 622 18.2 7.143 0.5 45 0.7 5.8 45-64 800 24.1 9,046 0.7 57 296 8.9 3,345 0.6 377 1,080 32.5 12,312 0.5 53 65-74 7.7 31 0.5 20 5 9.6 23 0.5 137 19 36.5 190 0.5 36 75-84 1 5.3 12 0.9 11 0 0.0 0 0.0 0 13 68.4 156 0.7 65 0.0 0 0.0 0 0.0 0 0 0 85 and older 0 0 0 0.0 0.0 0 0.0

TABLE ND.7B MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY,

BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c} NONDUAL BENEFICIARIES, RHODE ISLAND, 2005

		ANTIC	CONVULSA	NT			P	ANTIVIRAL				UL	CER DRUGS		
			Number of	Mean				Number of	Mean				Number of	Mean	
		Users	Benefit N	lumber of	Mean		Users	Benefit N	lumber of	Mean		Users	Benefit N	lumber of	Mean
		as %	Months		Rx \$ per		as %	Months		Rx \$ per		as %	Months		Rx \$ per
Danafician, Characteristics	Number of	of All	Among	Benefit		Number of	of All	Among	Benefit	Benefit	Number of	of All	Among		
Beneficiary Characteristics	Users	Benes	Users	Month	Month	Users	Benes	Users	Month	Month	Users	Benes	Users	Month	Month
Male, Other Eligibles															
All Ages	126	8.0	1,263	0.6	38	34	0.2	378	0.4	10	268	1.7	2,702	0.4	27
5 and younger	6	0.1	29	0.6	43	3	0.1	35	0.1	1	26	0.6	211	0.3	10
6-14	36	0.7	406	0.7	44	10	0.2	120	0.5	7	39	0.7	448	0.3	19
15-20	25	1.0	252	0.8	60	4	0.2	48	0.8	9	22	0.9	218	0.4	30
21-44	25	8.0	229	0.4	8	9	0.3	87	0.4	18	44	1.3	403	0.4	15
45-64	14	1.9	142	0.3	9	5	0.7	56	0.4	10	28	3.9	277	0.3	12
65-74	4	2.2	44	0.9	84	2	1.1	20	0.2	9	43	23.6	467	0.4	37
75-84	12	8.9	113	0.4	17	0	0.0	0	0.0	0	43	31.9	459	0.4	41
85 and older	4	8.2	48	1.0	97	1	2.0	12	0.1	6	23	46.9	219	0.5	50
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2005 file for Rhode Island, released by CMS in 12/2008. This table was produced on 04/23/2009.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription (s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.7B includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

${\it TABLE~ND.7C}\\ {\it MEDICAID~PHARMACY~BENEFIT~USE~AND~REIMBURSEMENT~FOR~SIXTH~TO~EIGHTH~TOP~DRUG~GROUPS~SEPARATELY,}$

BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c} NONDUAL BENEFICIARIES, RHODE ISLAND, 2005

		ANALG	SESICS - Nard	otic	_			HODE ISLAND TIASTHMATIO				ANTIH	IYPERLIPIDE	MIC	
		Users as %	Number of Benefit N Months	Rx per l			Users as %	Months		Mean Rx \$ per		Users as %	Months		Mean Rx \$ per
Beneficiary Characteristics	Number of Users	of All Benes	Among Users	Benefit Month	Benefit Month	Number of Users	of All Benes	Among Users	Benefit Month		Number of Users	of All Benes	Among Users	Benefit Month	Benefit Month
All	12,869	21.5	143,882	0.4	\$22	10,329	17.3	115,287	0.4	\$25	4,738	7.9	53,544	0.6	\$48
Female	12,003	21.5	143,002	0.4	ΨZZ	10,323	17.5	113,207	0.4	\$23	4,730	1.5	33,344	0.0	ΨΨΟ
All Females	8,513	25.3	95,628	0.4	19	6,866	20.4	76,941	0.4	26	3,033	9.0	34,522	0.6	48
Female, Disable	,	20.0	33,020	0.4	13	0,000	20.4	70,541	0.4	20	0,000	5.0	04,022	0.0	40
All Ages	7,347	67.1	84,631	0.4	21	5,812	53.1	66,714	0.4	28	2,654	24.2	30,660	0.6	49
5 and younger	14	4.7	167	0.4	6	104	34.6	1,126	0.4		2,034	0.0	0	0.0	0
6-14	52	7.2	612	0.2	1	231	32.0	2,687	0.3		0	0.0	0	0.0	0
15-20	93	16.4	1,061	0.1	3	145	25.6	1,675	0.3		3	0.5	36	0.6	37
21-44	2,882	74.4	33,207	0.4	15	1,786	46.1	20,583	0.3		410	10.6	4,706	0.5	42
45-64	4,227	79.0	48,712	0.4	25	3,487	65.2	39,962	0.4	33	2,182	40.8	25,227	0.6	51
65-74	61	56.5	662	0.3	8	51	47.2	588	0.5		51	47.2		0.6	53
75-84	16	88.9	186	0.3	9	8	44.4	93	0.3		8	44.4		0.6	44
85 and older	2	50.0	24	0.1	1	0	0.0	0	0.0		0	0.0	0	0.0	0
Female, Other El															
All Ages	1,166	5.1	10,997	0.2	3	1,054	4.6	10,227	0.3	10	379	1.7	3,862	0.5	39
5 and younger	14	0.4	135	0.1	1	110	2.9	986	0.2		0	0.0	0	0.0	0
6-14	61	1.2	652	0.1	1	279	5.4	2,806	0.2		1	0.0	12	0.6	14
15-20	94	2.9	949	0.1	1	111	3.4	1,123	0.2	6	2	0.1	24	0.6	60
21-44	619	7.2	5,451	0.2	2	357	4.1	3,284	0.3	8	64	0.7	552	0.5	15
45-64	215	18.6	2,006	0.2	3	91	7.9	863	0.3	15	84	7.3	797	0.5	29
65-74	89	23.6	1,028	0.2	4	47	12.5	556	0.3	27	142	37.7	1,532	0.5	45
75-84	42	21.6	462	0.2	3	38	19.6	411	0.3	20	70	36.1	765	0.6	51
85 and older	32	34.8	314	0.4	11	21	22.8	198	0.6	48	16	17.4	180	0.7	54
Male															
All Males	4,356	16.7	48,254	0.4	28	3,463	13.2	38,346	0.4	22	1,705	6.5	19,022	0.6	47
Male, Disabled															
All Ages	3,908	39.2	44,108	0.4	30	2,577	25.9	29,384	0.4	26	1,486	14.9	16,876	0.6	48
5 and younger	26	5.1	298	0.1	1	154	30.2	1,698	0.3	13	2	0.4	21	0.4	14
6-14	88	5.4	1,021	0.1	2	533	32.5	6,147	0.3	18	6	0.4	69	0.3	20
15-20	119	12.0	1,379	0.2	3	200	20.2	2,315	0.3	13	7	0.7	78	0.3	18
21-44	1,571	45.9	17,784	0.4	20	578	16.9	6,605	0.3	22	315	9.2	3,554	0.5	39
45-64	2,070	62.3	23,284	0.5	40	1,077	32.4	12,228	0.5	35	1,122	33.8	12,769	0.6	51
65-74	26	50.0	246	0.5	56	21	40.4	223	0.6	38	24	46.2	265	0.5	45
75-84	8	42.1	96	0.5	57	14	73.7	168	0.6	43	10	52.6	120	0.8	63
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

TABLE ND.7C MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY,

BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c} NONDUAL BENEFICIARIES, RHODE ISLAND, 2005

					NONDU	JAL DENEFICI	AKIES, K	HODE ISLAND	, 2005						
	-	ANALO	GESICS - Naro	otic			AN	FIASTHMATIC)			ANTIF	HYPERLIPIDE	MIC	
			Number of	Mean				Number of	Mean				Number of	Mean	
		Users	Benefit N	umber of	Mean		Users	Benefit N	lumber of	Mean		Users	Benefit N	Number of	Mean
		as %	Months	Rx per l	Rx \$ per		as %	Months	Rx per	Rx \$ per		as %	Months	Rx per	Rx \$ per
Beneficiary	Number of	of All	Among	Benefit	Benefit	Number of	of All	Among	Benefit	Benefit	Number of	of All	Among	Benefit	Benefit
Characteristics	Users	Benes	Users	Month	Month	Users	Benes	Users	Month	Month	Users	Benes	Users	Month	Month
Male, Other Elig	ibles														
All Ages	448	2.8	4,146	0.2	6	886	5.5	8,962	0.3	10	219	1.4	2,146	0.6	35
5 and younger	19	0.5	185	0.1	1	209	5.2	1,971	0.3	6	0	0.0	0	0.0	0
6-14	55	1.0	597	0.1	1	431	8.2	4,576	0.3	7	1	0.0	9	0.3	12
15-20	79	3.1	817	0.1	1	98	3.8	971	0.3	11	1	0.0	12	0.3	18
21-44	142	4.4	1,060	0.3	5	57	1.7	538	0.3	6	43	1.3	389	0.5	13
45-64	62	8.6	513	0.3	2	22	3.0	156	0.4	10	65	9.0	552	0.6	21
65-74	32	17.6	350	0.3	17	24	13.2	270	0.4	32	59	32.4	638	0.6	53
75-84	40	29.6	433	0.3	18	30	22.2	327	0.6	51	42	31.1	456	0.6	44
85 and older	19	38.8	191	0.3	13	15	30.6	153	0.4	26	8	16.3	90	0.7	49
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2005 file for Rhode Island, released by CMS in 12/2008. This table was produced on 04/23/2009.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription (s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.7C includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

TABLE ND.7D

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR NINTH AND TENTH TOP DRUG GROUPS

SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c} NONDUAL BENEFICIARIES, RHODE ISLAND, 2005

ANTIDIABETIC ANTIHYPERTENSIVE Number of Mean Number of Mean Users Benefit Number of Mean Users Benefit Number of Mean Rx per Rx \$ per as % Months as % Months Rx per Rx \$ per Benefit Beneficiary Number of of All Among Benefit Number of of All Among Benefit Benefit Number of Number of Characteristics Benes Beneficiaries Benefit Months Users Users Month Month Users Benes Users Month Month ΑII 4.567 7.6 51,376 0.5 \$41 5.506 9.2 61.442 0.4 \$21 59.785 357.987 **Female** All Females 3,073 9.1 34,712 0.5 42 3,303 9.8 37,118 0.4 23 33,639 196,040 Female, Disabled All Ages 2,708 24.7 31,030 0.5 43 2,740 25.0 31,365 0.3 23 10,945 117,281 56 2 5 and younger 1 0.3 12 0.4 4 1.3 42 0.4 301 2,632 6-14 6 8.0 72 1.0 38 53 7.3 594 0.6 9 722 7,742 15-20 10 1.8 114 0.3 17 29 5.1 342 0.4 8 567 5.729 488 5,491 428 3,873 21-44 12.6 0.5 39 11.1 4,859 0.3 18 41,648 45-64 2,130 39.8 24,515 0.5 45 2,133 39.9 24,468 0.3 24 5,352 58,102 64 41 78 65-74 59.3 718 0.5 72.2 883 0.3 25 108 1,176 8 96 32 18 75-84 44.4 0.5 51 14 77.8 165 0.5 204 25.0 30 85 and older 25.0 12 1.0 12 12 0.9 4 48 Female, Other Eligibles All Ages 365 1.6 3,682 0.5 30 563 2.5 5,753 0.4 22 22,694 78,759 0 0.0 0 0.0 0 0.0 12 3,816 9,833 1.0 6 5 and younger 2 0.0 20 1.0 22 43 0.8 452 0.7 7 5.134 20,987 6-14 15-20 12 0.4 109 0.6 27 7 0.2 65 0.6 4 3,273 11,558 21-44 61 0.7 506 0.6 14 95 1.1 780 0.6 13 8,651 24,775 45-64 74 6.4 666 0.5 26 81 7.0 744 0.5 21 1,157 5,025 65-74 129 34.2 1.396 0.4 36 193 51.2 2.132 0.3 26 377 3.649 75-84 59 30.4 669 0.4 31 99 51.0 1,080 0.3 26 194 1,996 85 and older 28 30.4 316 0.7 37 44 47.8 488 0.5 28 92 936 Male All Males 1,494 16,664 0.5 40 2,203 24,324 5.7 8.4 0.4 19 26,146 161,947 Male. Disabled All Ages 1,319 13.2 14,915 1,835 20,518 20 104,620 0.5 41 18.4 0.4 9,961 2 0.4 24 0.3 14 20 3.9 197 9 510 4,540 5 and younger 0.5 6-14 15 0.9 157 0.6 47 187 11.4 2,043 0.6 9 1,640 17,468 15-20 28 2.8 336 0.4 31 73 7.4 804 0.6 9 990 10,218 21-44 255 7.4 2.937 0.5 40 345 10.1 3.851 0.3 18 3.426 36,793 45-64 989 29.8 11,106 0.5 42 1,171 35.2 13,185 0.3 23 3,324 34,847 65-74 23 44.2 271 0.3 37 27 51.9 294 0.3 23 52 536 75-84 7 36.8 84 0.4 18 12 63.2 144 0.4 48 19 218 0.0 0 0 0.0 0 0 0 85 and older 0 0.0 0 0 0.0

TABLE ND.7D MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR NINTH AND TENTH TOP DRUG GROUPS

SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGEa, b, c

NONDUAL BENEFICIARIES, RHODE ISLAND, 2005

	-	1A	NTIDIABETIC				ANTII	HYPERTENSI	VE			
			Number of	Mean				Number of	Mean			
		Users	Benefit N	umber of	Mean		Users	Benefit N	umber of	Mean		
		as %	Months	Rx per I	Rx \$ per		as %	Months	Rx per l	Rx \$ per		
Beneficiary	Number of	of All	Among	Benefit	Benefit	Number of	of All	Among	Benefit	Benefit	Number of	Number of
Characteristics	Users	Benes	Users	Month	Month	Users	Benes	Users	Month	Month	Beneficiaries E	Benefit Months
Male, Other Eligi	ibles											
All Ages	175	1.1	1,749	0.5	26	368	2.3	3,806	0.5	15	16,185	57,327
5 and younger	0	0.0	0	0.0	0	3	0.1	19	0.8	5	4,007	10,397
6-14	8	0.2	85	0.4	9	78	1.5	827	0.6	6	5,280	22,137
15-20	3	0.1	24	0.3	6	24	0.9	245	0.5	6	2,549	10,834
21-44	23	0.7	163	0.6	16	37	1.1	385	0.6	12	3,260	7,861
45-64	43	5.9	411	8.0	15	65	9.0	577	0.6	12	723	2,571
65-74	57	31.3	596	0.4	32	87	47.8	924	0.4	26	182	1,688
75-84	27	20.0	302	0.5	39	54	40.0	607	0.3	21	135	1,335
85 and older	14	28.6	168	0.6	27	20	40.8	222	0.4	16	49	504
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0

Source: Data for this table are from the MAX 2005 file for Rhode Island, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Table ND.7D includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = Deneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription (s) or pharmacy; \$ = Medicaid reimbursement.

TABLE ND.8 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,

BY BENEFICIARY CHARACTERISTIC^{a, b} NONDUAL BENEFICIARIES, RHODE ISLAND, 2005

Beneficiary		Number of Dy per Benefit	Number of All-Year Nursing	Benefit Months Among All- Year Nursing Facility
Characteristics	Rx \$ per Benefit Month	Month		Residents
All	\$438	5.6	428	4,987
Age				
0-64	453	5.4	359	4,227
65-74	481	7.6	12	124
75-84	320	5.5	19	212
85 and older	335	6.5	38	424
Unknown	0	0.0	0	0
Gender				
Female	424	5.7	204	2,385
Male	451	5.4	224	2,602
Unknown	0	0.0	0	0
Race				
White	436	5.4	314	3,720
African American	514	5.3	28	327
Other/unknown	419	6.3	86	940
Basis of Eligibility				
Aged	350	6.4	60	661
Disabled	451	5.4	368	4,326
Adults	0	0.0	0	0
Children	0	0.0	0	0
Unknown	0	0.0	0	0

c. inedicate basis or eligibility is classified as, aged, disabled, adultis, and children't ne disabled group includes behaliciant or all yage who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicard Services; MAX = Medicard Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy; \$ = Medicard reimbursement.

Source: Data for this table are from the MAX 2005 file for Rhode Island, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Table ND.8 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their 2005 Medicaid enrollment. A total of 322 beneficiaries who were

in nursing facilities for part of their enrollment and their 3,300 benefit months were excluded from the analysis. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability

TABLE ND.9 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,

BY BRAND STATUS AND THERAPEUTIC CATEGORYA, b, c, d, e NONDUAL BENEFICIARIES, RHODE ISLAND, 2005

Number of Rx per Benefit \$ per Benefit Month Among

Month Among Users \$ per Rx Users Users

																As a Percentage	
			Off-				Off-				Off-					of All-Year	
Theorem	Р		Patent		P	atented			Р		Patent		Tatal Niversia		Ni mala an af		Number of
Therapeutic Category	Total	Brand- Name	Brand- Name G	eneric	Total	Brand- Name	Brand- Name G	eneric	Total	Brand- Name	Name G	2onorio	Total Number of Rx	Total Rx \$	Number of Users	Facility Residents	Benefit Months
Anti-infective Agents	0.4	0.1	0.0	0.3	\$32	\$24	\$2	\$6	\$82	\$216	\$83	\$23	1,032	\$84,834	226	52.8	2,657
•					•	•	•	* -		•	*	•					,
Biologicals	0.0	0.0	0.0	0.0	0	0	0	0	0	0	0	0	0	0	0	0.0	0
Antineoplastic Agents	0.5	0.1	0.0	0.4	77	21	0	56	148	228	0	131	83	12,304	15	3.5	160
Endocrine/Metabolic Drugs	1.0	0.3	0.2	0.5	69	31	27	11	69	103	162	20	1,657	113,772	141	32.9	1,657
Cardiovascular Agents	1.7	0.6	0.0	1.0	59	43	0	16	36	70	24	15	3,666	130,666	193	45.1	2,203
Respiratory Agents	0.8	0.6	0.1	0.1	53	42	8	2	64	75	67	15	1,195	75,929	125	29.2	1,440
Gastrointestinal Agents	1.2	0.5	0.0	0.8	91	60	0	31	73	129	40	39	2,569	187,019	178	41.6	2,065
Genitourinary Agents	0.7	0.5	0.0	0.2	43	36	1	6	60	75	40	28	558	33,554	67	15.7	783
CNS Drugs	2.0	0.8	0.0	1.1	211	170	4	37	108	207	100	34	7,267	784,802	319	74.5	3,719
Stimulants/Anti-obesity/Anorexia	0.8	0.2	0.1	0.4	62	37	10	14	80	155	81	35	74	5,904	8	1.9	96
Miscellaneous Psychological/																	
Neurological Agents	0.9	0.9	0.0	0.0	164	164	0	0	180	180	0	0	252	45,393	24	5.6	276
Analgesics and Anesthetics	0.9	0.2	0.1	0.6	63	20	14	29	71	101	220	47	1,574	112,332	154	36.0	1,773
Neuromuscular Agents	1.6	0.7	0.1	0.8	168	121	10	36	106	165	112	48	4,134	436,930	221	51.6	2,604
Nutritional Products	0.7	0.0	0.0	0.6	11	1	2	9	16	22	85	14	341	5,513	42	9.8	493
Hematological Agents	1.4	0.3	0.0	1.1	56	48	0	8	41	186	9	7	1,136	46,032	75	17.5	823
Topical Products	0.7	0.2	0.0	0.5	34	22	2	10	47	91	53	23	2,163	101,531	255	59.6	2,981
Miscellaneous Products	0.3	0.1	0.1	0.1	35	3	20	11	129	49	294	85	39	5,043	12	2.8	144
Unknown Therapeutic Category	0.1	0.0	0.0	0.0	14	0	0	0	133	0	0	0	18	2,401	14	3.3	168
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	27,758	2,183,959	n.a.	n.a.	n.a.

a. Table ND.9 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 322 beneficiaries who were in nursing facilities for part of their enrollment and their 3,300 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2005. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615

e. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

In Rhode Island, 0.4 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. Bene Mo(s) = benefit month(s); CMS = Centers for Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS,

BY TOP-10 DRUG GROUP^{a, b, c, d} NONDUAL BENEFICIARIES, RHODE ISLAND, 2005

			Users				Among Users
Top 10 Drug Groups in Nursing Facilities	Total Medicaid Rx \$	Number of Users	As a Percentage of All-Year Nursing Facility Residents	Number of Benefit Monthsp	Number of Rx er Benefit Month	\$ per Rx	Rx \$ per Benefit Month
ANTIPSYCHOTICS	\$558,876	217	50.7	2,526	1.1	\$200	\$221
ANTICONVULSANT	413,105	264	61.7	3,114	1.1	118	133
ANTIDEPRESSANTS	189,511	308	72.0	3,639	0.9	60	52
ULCER DRUGS	137,101	156	36.4	1,783	0.9	89	77
DERMATOLOGICAL	80,530	485	113.3	5,725	0.3	51	14
ANALGESICS - Narcotic	73,679	116	27.1	1,313	0.7	82	56
ANTIHYPERLIPIDEMIC	60,518	82	19.2	937	0.9	75	65
MISC. ENDOCRINE	53,364	36	8.4	432	0.8	151	124
MISC PSYCHOTHERAPEUTIC AND NEUROLOGICAL	45,393	28	6.5	324	0.8	180	140
ANTIASTHMATIC	34,860	81	18.9	905	0.6	69	39
Total	1,646,937	1,773		20,698	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2005 file for Rhode Island, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Table ND.10 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 322 beneficiaries who were in nursing facilities for part of their enrollment and their 3,300 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. wedicald relinious/serient and action of the control of the con

Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$= Medicaid reimbursement.

TABLE ND.10A MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR TOP 10 DRUG GROUPS COMBINED AND FIRST

AND SECOND TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGEA, b, c, d NONDUAL BENEFICIARIES, RHODE ISLAND, 2005

	All Top 10	Drug Groups		ANTIPS	/CHOTICS				ANTICO	NVULSANT		
Beneficiary Characteristics	Number of Rx	Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Benefit Months	Mean Number of Rx		Number of Users	Users as % of All-Year Nursing Facility Residents	Benefit Months Among	Mean Number of Rx	
All	15,410	\$1,646,937	217	50.7	2,526	1.1	\$221	264	61.7	3,114	1.1	\$133
Female												
All Females	7,300	775,204	113	55.4	1,324	1.1	217	128	62.7	1,513	1.1	119
Female, Disabled												
All Ages	6,233	688,559	94	56.3	1,108	1.2	230	119	71.3	1,405	1.1	126
64 or younger	6,139	681,074	91	56.5	1,072	1.2	234	119	73.9	1,405	1.1	126
65-74	26	3,308	1	33.3	12	1.0	203	0	0.0	0	0.0	0
75-84	33	1,986	1	50.0	12	0.6	43	0	0.0	0	0.0	0
85 and older	35	2,191	1	100.0	12	1.2	132	0	0.0	0	0.0	0
Female, Other Eligibles												
All Ages	1,067	86,645	19	51.4	216	0.7	153	9	24.3	108	0.9	37
64 or younger	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	25	960	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	246	27,571	7	70.0	76	0.8	228	2	20.0	24	0.9	71
85 and older	796	58,114	12	48.0	140	0.7	112	7	28.0	84	0.8	28
Male												
All Males	8,110	871,733	104	46.4	1,202	1.1	226	136	60.7	1,601	1.2	145
Male, Disabled												
All Ages	7,334	812,187	95	47.3	1,102	1.1	234	127	63.2	1,501	1.2	151
64 or younger	7,188	801,712	92	46.5	1,066	1.1	238	126	63.6	1,498	1.2	151
65-74	146	10,475	3	100.0	36	0.8	97	1	33.3	3	1.0	92
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Male, Other Eligibles												
All Ages	776	59,546	9	39.1	100	0.7	135	9	39.1	100	0.8	54
64 or younger	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	250	21,874	3	75.0	36	0.9	192	1	25.0	12	1.2	36
75-84	200	13,656	1	14.3	4	1.0	173	5	71.4	52	0.5	22
85 and older	326	24,016	5	41.7	60	0.6	98	3	25.0	36	0.9	105
Unknown	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

a. Table ND.10A includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 322 beneficiaries who were

a. Table No. To includes the beneficiales represented by Cell LO in Table 1, those with resided in This gradies throughout their invention of their enrollment and their 3,300 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state. d. The top 10 drug groups were determined based on total 2005 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters

Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007). Bene Mo(s) = benefit month(s); BDE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10B

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY

AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGEa, b, c, d

NONDUAL BENEFICIARIES, RHODE ISLAND, 2005

		ANTIDEP	RESSANTS				ULCEF	RDRUGS				DERMAT	OLOGICAL		
Beneficiary Characteristics	Number of Users	Users as % of All-Year Nursing Facility Residents	Benefit Months Among			Number of Users	Users as % of All-Year Nursing Facility Residents	Benefit Months Among			Number of Users	Users as % of All-Year Nursing Facility Residents	Benefit Months Among	Mean Number of Rx	
All	308	72.0	3,639	0.9	\$52	156	36.4	1,783	0.9	\$77	485	113.3	5,725	0.3	\$14
Female															
All Females	150	73.5	1,781	0.9	52	61	29.9	711	0.8	72	207	101.5	2,457	0.2	12
Female, Disable	ed														
All Ages	119	71.3	1,418	0.9	54	44	26.3	525	0.8	80	182	109.0	2,171	0.2	13
64 or younger	114	70.8	1,358	0.9	55	43	26.7	513	0.8	81	180	111.8	2,147	0.2	13
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	1	33.3	12	0.2	3
75-84	3	150.0	36	0.6	36	0	0.0	0	0.0	0	1	50.0	12	0.3	14
85 and older	2	200.0	24	0.6	8	1	100.0	12	0.4	33	0	0.0	0	0.0	C
Female, Other E	Eligibles														
All Ages	31	83.8	363	0.9	45	17	45.9	186	0.9	49	25	67.6	286	0.2	11
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	C
65-74	2	100.0	24	1.0	40	0	0.0	0	0.0	0	0	0.0	0	0.0	C
75-84	6	60.0	72	0.8	36	3	30.0	36	1.0	69	6	60.0	72	0.2	8
85 and older	23	92.0	267	0.8	48	14	56.0	150	0.8	45	19	76.0	214	0.2	12
Male															
All Males	158	70.5	1,858	0.9	52	95	42.4	1,072	0.9	80	278	124.1	3,268	0.3	15
Male, Disabled															
All Ages	136	67.7	1,594	0.9	55	80	39.8	909	0.9	81	247	122.9	2,905	0.3	15
64 or younger	133	67.2	1,567	0.9	55	75	37.9	867	0.9	84	245	123.7	2,881	0.3	15
65-74	3	100.0	27	1.0	69	5	166.7	42	0.9	36	2	66.7	24	0.4	15
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	C
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	C
Male, Other Elig	jibles														
All Ages	22	95.7	264	0.7	38	15	65.2	163	0.9	73	31	134.8	363	0.4	21
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	C
65-74	5	125.0	60	0.8	58	2	50.0	24	1.0	103	10	250.0	120	0.4	27
75-84	5	71.4	60	0.7	59	6	85.7	64	0.9	63	8	114.3	96	0.3	13
85 and older	12	100.0	144	0.6	21	7	58.3	75	0.8	71	13	108.3	147	0.3	22
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	C

Source: Data for this table are from the MAX 2005 file for Rhode Island, released by CMS in 12/2008. This table was produced on 04/23/2009.

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.10B includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 322 beneficiaries who were in nursing facilities for part of their enrollment and their 3,300 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. wedicald relinibisherient and action of the control of the cont

TABLE ND.10C

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY

AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGEA, b, c, d NONDUAL BENEFICIARIES, RHODE ISLAND, 2005

	-	ANALGES	ICS - Narco	tic		IAL BENEFICI		ERLIPIDEMI				MISC. E	NDOCRINE		
Beneficiary Characteristics	Number of Users	Users as % of All- Year Nursing Facility Residents				Number of Users	Users as % of All- Year Nursing Facility Residents	Number of Benefit Months Among Users			Number of Users	Users as % of All- Year Nursing Facility Residents		Mean Number of Rx	
All	116	27.1	1,313			82		937				8.4			
Female															
All Females	51	25.0	602	0.7	44	39	19.1	438	0.9	61	23	11.3	276	0.8	89
Female, Disable	ed														
All Ages	41	24.6	492	0.7	52	31	18.6	358	0.9	65	19	11.4	228	0.8	9:
64 or younger	40	24.8	480	0.7	54	31	19.3	358	0.9	65	18	11.2	216	0.8	9:
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	1	33.3	12	1.0	7
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0) (
85 and older	1	100.0	12	0.2	1	0	0.0	0	0.0	0	0	0.0	0	0.0) (
Female, Other E	Eligibles														
All Ages	10	27.0	110	0.6	8	8	21.6	80	0.7	40	4	10.8	48	1.0	74
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0) (
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	(
75-84	1	10.0	12	0.9	17	4	40.0	32	1.0	49	0	0.0	0	0.0) (
85 and older	9	36.0	98	0.5	7	4	16.0	48	0.5	35	4	16.0	48	1.0	74
Male															
All Males	65	29.0	711	0.7	66	43	19.2	499	0.8	68	13	5.8	156	0.8	186
Male, Disabled															
All Ages	56	27.9	612	0.7	73	37	18.4	435	0.8	69	11	5.5	132	0.9	21
64 or younger	54	27.3	606	0.7	72	36	18.2	432	0.8	70	10	5.1	120	0.8	224
65-74	2	66.7	6	2.3	110	1	33.3	3	0.7	48	1	33.3	12	1.0	82
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0) (
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0) (
Male, Other Elig	jibles														
All Ages	9	39.1	99	0.6	26	6	26.1	64	1.0	58	2	8.7	24	0.6	4
64 or younger	0	0.0	0	0.0	0	0	0.0	0			0	0.0	0		
65-74	2	50.0				3	75.0	36				25.0			
75-84	1	14.3				2		16				0.0			
85 and older	6	50.0					8.3	12		67	1	8.3			
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	(

a. Table ND.10C includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 322 beneficiaries who were in nursing facilities for part of their enrollment and their 3,300 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each

group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2005 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10D

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR NINTH AND TENTH TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{2, b, c, d}

NONDUAL BENEFICIARIES, RHODE ISLAND, 2005

MISC PSYCHOTHERAPEUTIC AND NEUROLOGICAL

ANTIASTHMATIC

Beneficiary Characteristics	Number of Users	Users as % of All-Year Nursing Facility Residents	Benefit Months	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Benefit Months Among	Mean Number of Rx	Mean Rx \$	All-Year Nursing Facility Residents	Benefit Months Among All- Year Nursing Facility Residents
All	28	6.5	324	0.8	\$140	81	18.9	905	0.6	\$39	428	4,987
Female												
All Females	13	6.4	144	0.9	226	43	21.1	505	0.6	45	204	2,385
Female, Disable	d											
All Ages	5	3.0	60	0.9	369	38	22.8	445	0.6	44	167	1,983
64 or younger	5	3.1	60	0.9	369	38	23.6	445	0.6	44	161	1,911
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	3	36
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	2	24
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	1	12
Female, Other E	ligibles											
All Ages	8	21.6	84	0.9	124	5	13.5	60	0.6	49	37	402
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	2	13
75-84	1	10.0	4	1.3	174	2	20.0	24	0.4	20	10	112
85 and older	7	28.0	80	0.9	121	3	12.0	36	0.8	68	25	277
Male												
All Males	15	6.7	180	0.7	71	38	17.0	400	0.5	31	224	2,602
Male, Disabled												
All Ages	9	4.5	108	0.9	91	33	16.4	340	0.6	34	201	2,343
64 or younger	9	4.5	108	0.9	91	32	16.2	328	0.5	32	198	2,316
65-74	0	0.0	0	0.0	0	1	33.3	12	1.1	96	3	27
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
Male, Other Eligi	ibles											
All Ages	6	26.1	72	0.3	42	5	21.7	60	0.3	12	23	259
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
65-74	1	25.0	12	0.1	1	0	0.0	0	0.0	0	4	48
75-84	3	42.9	36	0.5	63	1	14.3	12	0.1	1	7	76
85 and older	2	16.7	24	0.2	31	4	33.3	48	0.4	15	12	135
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0

a. Table ND.10D includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 322 beneficiaries who were in nursing facilities for part of their enrollment and their 3,300 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2005 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.11 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS, BY BENEFICIARY CHARACTERISTICa,b RHODE ISLAND, 2005

	Number of Beneficiaries with at Least	Percentage of Beneficiaries with at Least	Number of Part D Excluded Rx	Total Number	Part D Excluded Rx		F	Part D Excluded Rx \$ as a	Total Number
Beneficiary Characteristics	One Part D Excluded Rx	One Part D Excluded Rx	per Beneficiary	Part D Excluded Rx	\$ per Beneficiary	Total Part D Excluded Rx \$		ercentage of All Nondual Rx \$	of Beneficiaries
All	12,388	20.7	1.4	85,587	\$20	\$1,178,259	\$14	2.1	59,785
Age	,			,	*	4 1,11 0,200	***		,
5 and younger	573	6.6	0.2	1,583	2	19,989	13	3.5	8,634
6-14	1,036	8.1	0.3	,	6	77,867	23	3.2	12,776
15-20	597	8.1	0.3	2,340	11	78,602	34	4.1	7,379
21-44	4,213	21.9	1.4		18	339,120	13	1.8	19,210
45-64	5,369	50.9	4.5		60	630,347	13	2.0	10,556
65-74	342	47.6	2.6	1,872	23	16,484	9	1.5	719
75-84	180	49.2	3.0	1,111	30	11,049	10	1.7	366
85 and older	78	53.8	4.3	623	33	4,801	8	1.4	145
Unknown	0	0.0	0.0	0	0	0	0	0.0	0
Basis of Eligibility	С								
Aged	474	46.3	2.5	2,596	22	22,722	9	1.5	1,023
Disabled	9,649	46.2	3.7	77,720	53	1,103,995	14	2.1	20,906
Adults	1,061	7.3	0.2	2,573	2	26,311	10	3.8	14,583
Children	1,094	4.8	0.1	2,256	1	20,677	9	2.1	22,960
Unknown	110	35.1	1.4	442	15	4,554	10	1.4	313
Gender									
Female	8,102	24.1	1.8	59,511	25	833,545	14	2.4	33,639
Male	4,286	16.4	1.0	26,076	13	344,714	13	1.6	26,146
Unknown	0	0.0	0.0	0	0	0	0	0.0	0
Race									
White	6,609	28.2	2.4	55,602	35	813,556	15	2.3	23,471
African American	1,183	21.2	1.2	6,810	13	71,675	11	1.4	5,578
Other/unknown	4,596	15.0	0.8	23,175	10	293,028	13	1.8	30,736
Use of Nursing Fa	cilities ^d								
Entire year	285	66.6	10.0	4,295	92	39,533	9	1.8	428
Part year	245	76.1	8.1	2,599	92	29,635	11	1.6	322
None	11,858	20.1	1.3	78,693	19	1,109,091	14	2.1	59,035
Maintenance Assis	stance Status								
Cash	8,790	35.9	2.9	71,317	41	1,010,490	14	2.1	24,452
Medically needy	48	57.1	3.2	272	47	3,946	15	1.5	84
Poverty related	445	5.3	0.1	1,064	1	9,755	9	2.3	8,468
Other/unknown	3,105	11.6	0.5	12,934	6	154,068	12	2.0	26,781

Source: Data for this table are from the MAX 2005 file for Rhode Island, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Table ND.11 includes the beneficiaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month

b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.12 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC^{a,b} RHODE ISLAND, 2005

Beneficiary Characteristics	Number Rx per	Rx \$ per Benefit Month	\$ per Rx	Barbiturate \$ per Benefit Month	Benzodiazepine \$ per Benefit Month	Number of
All	0.2	\$3	\$14	\$0	\$2	357,987
Age		•	***	**	•-	,
5 and younger	0.1	1	13	0	0	27,402
6-14	0.0	1	23	0	0	68,334
15-20	0.1	2	34	0	0	38,339
21-44	0.2	3	13	0	2	111,077
45-64	0.5	6	13	0	3	100,545
65-74	0.3	2	9	0	0	7,049
75-84	0.3	3	10	0	1	3,753
85 and older	0.4	3	8	0	1	1,488
Unknown	0.0	0	0	0	0	0
Basis of Eligibility ^c						
Aged	0.3	2	9	0	0	10,091
Disabled	0.4	5	14	0	2	221,901
Adults	0.1	1	10	0	0	39,186
Children	0.0	0	9	0	0	84,311
Unknown	0.2	2	10	0	1	2,498
Gender						
Female	0.3	4	14	0	2	196,040
Male	0.2	2	13	0	1	161,947
Unknown	0.0	0	0	0	0	0
Race						
White	0.3	5	15	0	2	168,561
African American	0.2	2	11	0	1	38,264
Other/unknown	0.2	2	13	0	1	151,162
Use of Nursing Facil	ities ^d					
Entire year	0.9	8	9	0	3	4,987
Part year	0.8	9	11	0	4	3,300
None	0.2	3	14	0	2	349,700
Maintenance Assista	ance Status					
Cash	0.4	5	14	0	2	201,380
Medically needy	0.4	5	15	0	2	726
Poverty related	0.0	0	9	0	0	23,254
Other/unknown	0.1	1	12	0	1	132,627

a. Table ND.12 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2005.

b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include they barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficaries of any age who were determined to be eligible because of disability

or blindness. The children's group includes children receiving foster care and adoptive services.

d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

TABLE ND.13 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG NONDUALS a,b,c RHODE ISLAND, 2005

Drug Category	Number of Users	Rx \$ per User	Total Rx \$	Rx \$ as a Percentage of All Part D Excluded Rx \$	Total Number Rx.	\$ per Rx	Number Rx as a Percentage of All Part D Excluded Rx
All	17,911	\$66	\$1,178,259	100.0	85,587	\$14	100.0
Anorexia or weight loss/gain	13	205	2,668	0.2	48	56	0.1
Fertility drugs	1	126	126	0.0	3	42	0.0
Drugs for cosmetic purposes	40	15	605	0.1	57	11	0.1
Cough and cold medications	3,278	55	181,317	15.4	7,134	25	8.3
Vitamins and minerals	879	90	79,024	6.7	3,878	20	4.5
Non-prescription drugs	7,630	25	187,312	15.9	32,986	6	38.5
Barbiturates	204	79	16,159	1.4	2,185	7	2.6
Benzodiazepines	5,154	110	564,389	47.9	36,529	15	42.7
Other Part D Excl Rx Drugs	712	206	146,659	12.4	2,767	53	3.2

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.13 includes the beneficaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2005. A user is a beneficiary who had at least one prescription filled for a Part D excluded drug in 2005. A beneficiary who sused drugs from two or more Part D excluded categories was counted as a user for each category. Therefore, the sum of users across drug categories may exceed the total number of individual users as noted on Table ND11.

b. Includes OTC drugs as well as prescription drugs.

c. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

APPENDIX TABLE A.1 CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY^{a, b} NONDUAL BENEFICIARIES, RHODE ISLAND, 2005

	NONDUAL BENEFICIARIES, RHODE ISLAND, 2005 Number of Beneficiaries Number of Benefit Months											
Beneficiary Characteristics	All	Aged	Blind/ Disabled	Adults	Children	Other/ Unknown	All	Aged	Blind/ Disabled	Adults	Children	Other/ Unknown
All	179,583	1,024	24,561	54,253	99,432	313	1,810,921	10,180	272,672	524,366	1,001,153	2,550
Age												
5 and younger	36,970	0	1,418	0	35,552	0	358,076	0	15,354	0	342,722	0
6-14	47,891	0	4,036	6	43,849	0	507,189	0	46,960	59	460,170	0
15-20	25,196	0	2,531	2,752	19,900	13	251,685	0	28,868	25,447	197,312	58
21-44	52,232	1	7,621	44,368	124	118	515,738	12	84,476	429,521	890	839
45-64	16,054	1	8,754	7,112	6	181	165,748	9	94,832	69,207	50	1,650
65-74	727	553	160	13	0	1	7,223	5,389	1,712	119	0	3
75-84	367	328	37	2	0	0	3,765	3,330	422	13	0	0
85 and older	145	141	4	0	0	0	1,488	1,440	48	0	0	0
Unknown	1	0	0	0	1	0	9	0	0	0	9	0
Gender												
Female	102,929	662	12,341	40,476	49,138	312	1,044,711	6,637	137,700	401,263	496,562	2,549
Male	76,654	362	12,220	13,777	50,294	1	766,210	3,543	134,972	123,103	504,591	1
Unknown	0	0	0	0	0	0	0	0	0	0	0	0
Race												
White	62,750	188	12,430	21,621	28,276	235	649,359	1,986	138,452	213,227	293,832	1,862
African American	15,759	94	2,804	4,656	8,194	11	164,296	985	31,141	46,082	85,997	91
Other/unknown	101,074	742	9,327	27,976	62,962	67	997,266	7,209	103,079	265,057	621,324	597
Use of Nursing Facilities ^c												
Entire year	428	60	368	0	0	0	4,987	661	4,326	0	0	0
Part year	324	42	282	0	0	0	3,370	378	2,992	0	0	0
None	178,831	922	23,911	54,253	99,432	313	1,802,564	9,141	265,354	524,366	1,001,153	2,550
Maintenance Assistance Statu	s											
Cash	59,238	181	21,069	11,298	26,690	0	628,500	1,892	237,935	111,663	277,010	0
Medically needy	98	3	74	21	0	0	932	27	703	202	0	0
Poverty related	33,181	3	0	1,484	31,381	313	328,899	36	0	9,510	316,803	2,550
Other/unknown	87,066	837	3,418	41,450	41,361	0	852,590	8,225	34,034	402,991	407,340	0
Managed Care (MC) Status												
Fee-for-service (FFS) all year	27,591	1,005	19,518	2,041	4,721	306	288,085	9,990	214,521	15,395	45,696	2,483
FFS part year, with Rx claims	5,088	12	866	2,108	2,099	3	52,661	116	9,926	20,536	22,053	30
FFS part year, no Rx claims	27,106	6	522	10,434	16,140	4	229,388	62	5,431	84,586	139,272	37
MC all year, with Rx claims	2,000	0	82	1,111	807	0	20,889	0	927	11,393	8,569	0
MC all year, no Rx claims	117,798	1	3,573	38,559	75,665	0	1,219,898	12	41,867	392,456	785,563	0

a. Table A.1 includes the beneficiaries represented by Cell J of Table 1. Benefit months are months during which beneficiaries had pharmacy benefit coverage.
b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability

or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories

are not consistent with basis of eligibility.

c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

APPENDIX TABLE A.2

MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS^a NONDUAL BENEFICIARIES, RHODE ISLAND, 2005

	Beneficia Benefit Month	aries and ns in Cell J of				
	Tab	le 1	Included in Ce	ell K of Table 1	Excluded from (Cell K of Table 1
	Number of Beneficiaries	Number of Benefit Months	Number of Beneficiaries	Number of Benefit Months	Number of Beneficiaries	Number of Benefit Months
All	179,583	1,810,921	59,785	357,987	0	1,452,934
Fee-for-service (FFS) all year	27,591	288,085	27,591	288,085	0	0
FFS part year, with Rx claims	5,088	52,661	5,088	24,671	0	27,990
FFS part year, with no Rx claims	27,106	229,388	27,106	45,231	0	184,157
Managed care (MC) all year, with Rx claims	2,000	20,889	0	0	0	20,889
MC all year, with no Rx claims	117,798	1,219,898	0	0	0	1,219,898

Source: Data for this table are from the MAX 2005 file for Rhode Island, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Benefit months are months during which beneficiaries had pharmacy benefit coverage.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.